Sunday , May 22 2022

Israelis discovered a new treatment for aggressive brain tumors


A new treatment for aggressive brain tumors (glioblastoma) shows a great promise, according to a report by Israeli scientists recently published in the journal Nucleic Acid Research.

Glioblastoma is a serious and incurable brain cancer. Patients who receive this diagnosis usually have 11 to 20 months of life. One of the main difficulties in treating this cancer is that cells rapidly increase resistance to chemo.

A team led by Professor Rotome Karni and dr. student Makim Mogilevsky at the Institute of Medical Research of the Hebrew University-Israel Canada (IMRIC) has designed a molecule that inhibits the growth of glioblastoma tumors by regulating the proteins it produces.

Karni explained that the MKNK2 gene produces two different protein products through a process called "RNA Alternative Merger". These proteins have two opposite functions: MNK2a inhibits cancer growth, while MNK2b supports cancer cancer.

Karney's new molecule moves the membrane of MKNK2 so that the production of tumor-stimulating protein decreases, while the production of tumor-suppressing proteins increases. As a result, cancerous tumors decrease or die.

"This breakthrough molecule not only kills the tumor cells alone, but also the ability to help former chemotherapy-resistant cells become sensitive again to chemotherapy," said Karni.

The future includes customizing specific treatment for patients

In the study, laboratory mice were injected with human tumors of glioblastoma cells and tumors developed.

In these mice treated with the new molecule, tumors were completely reduced or dying, as opposed to control mice treated with an inactive molecule.

"Our research presents a new approach to the treatment of glioblastoma. In the future, we will be able to adjust the treatment for patients based on the amount of cancer-inhibiting proteins that tumors produce," Karni said.

The patent for this technology has been registered and approved in the United States and Europe via Iissum, technology transfer technology company of the Hebrew University.

Also, participation in the "Modulation of MKNK2 Alternative Jointing with Split -Swinging Oligonucleotide as a New Approach for the Treatment of Glioblastoma" was investigated by Adi Mogilevski from IMRIC; Odelia Shimshon and Eilon Iavin from the Institute of Medicine Research Institute of the Hebrew University Medical School; Saran Kumar and Eli Keshet from the Department of Developmental Biology and Cancer Research; and Florian Heid from the Laboratory of Chemistry and Biochemistry of RNA Biochemistry at the Freie Universitat in Berlin.

The funding comes from the German-Israel Foundation, the Israeli Innovation Agency, the Israeli Science Foundation, the Israeli Cancer Research Foundation, the Israeli Cancer Foundation, the Henri & Merilin Taub Foundation and the Carol Epstein Foundation.

Source link